Cargando…
2060. Evaluation of the real world incidence of integrase inhibitor resistance since adoption as guideline preferred therapy
BACKGROUND: There are limited data reporting real-world incidence of integrase inhibitor resistance (INSTI-R) since the approval and first-line treatment recommendation of INSTIs in the US. A recent analysis of the national surveillance data estimated INSTI-R to be 6.3%. The purpose of this study wa...
Autores principales: | Januszka, Jenna, Drwiega, Emily N, Burgos, Rodrigo M, Michienzi, Sarah M, Smith, Renata, Badowski, Melissa E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752527/ http://dx.doi.org/10.1093/ofid/ofac492.1682 |
Ejemplares similares
-
Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?
por: Januszka, Jenna E, et al.
Publicado: (2023) -
1518. Prevalence of Integrase Inhibitor Resistance within an Urban Clinic Network After Adoption as First-line Therapy
por: Januszka, Jenna E, et al.
Publicado: (2023) -
Antiretroviral drug–drug interactions: A comparison of online drug interaction databases
por: Drwiega, Emily N., et al.
Publicado: (2022) -
The race to a COVID-19 vaccine: opportunities and challenges in development and distribution
por: Burgos, Rodrigo M, et al.
Publicado: (2021) -
How to design and implement an outpatient antimicrobial stewardship programme
por: Drwiega, Emily N, et al.
Publicado: (2023)